The description of HDACs highly expressed in SS specimens and directly interacting with the SS18-SSX oncoproteins [9, 13–17] has paved the way to the evaluation of HDAC inhibitors (HDACi) in this malignancy. This evidence concerns the gene SSX2 and synovial sarcoma.